Cabaletta Bio, Inc. — FY2022 Form 10-K Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for B-cell-mediated autoimmune diseases. Its CABA platform includes CARTA therapies intended to reset the immune system through CD19-positive B-cell depletion and CAART therapies intended to selectively eliminate disease-causing B cells. This Form 10-K covers the fiscal year ended December 31, 2022; it is an annual filing rather than a quarterly report.
- Lead programs include CABA-201, DSG3-CAART for mucosal pemphigus vulgaris, and MuSK-CAART for MuSK-positive myasthenia gravis.
- DSG3-CAART was in the Phase 1 DesCAARTes trial, and MuSK-CAART entered the Phase 1 MusCAARTes trial in November 2022.
- CABA-201 was an IND-enabling/preclinical program at year-end. Management expected potential FDA IND clearance in the first half of 2023.
- The company had 60 employees at December 31, 2022, including 51 engaged in research and development.
Financial and operating metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $39.3 million | $32.5 million | +$6.8 million |
| General and administrative expense | $14.8 million | $13.8 million | +$1.0 million |
| Total operating expenses | $54.1 million | $46.3 million | +$7.8 million |
| Interest income | $1.2 million | $0.02 million | +$1.1 million |
| Net loss | $53.0 million | $46.3 million | Loss increased $6.7 million |
| Basic and diluted net loss per share | $1.81 loss | $1.80 loss | Higher loss per share |
| Cash used in operating activities | $46.4 million | $34.1 million | Use increased $12.3 million |
| Cash and cash equivalents | $81.6 million | $122.2 million | Declined $40.6 million |
| Short-term investments | $24.9 million | None reported | New balance |
| Cash, cash equivalents and investments | $106.5 million | $122.2 million | Declined $15.7 million |
| Accumulated deficit | $165.6 million | $112.6 million | Increased $53.0 million |
Research and development spending increased primarily from higher personnel costs, the $2.5 million IASO license upfront payment, increased DesCAARTes clinical trial costs, and MusCAARTes start-up costs. These increases were partly offset by lower manufacturing costs due to the timing of vector manufacturing activities. Stock-based compensation was $6.9 million, compared with $5.8 million in 2021.
Cash used in investing activities was $27.2 million, reflecting $49.8 million of investment purchases, $25.0 million of investment maturities, and $2.5 million of capital expenditures. Financing activities provided $33.0 million, primarily from the December 2022 equity and pre-funded warrant financing.
The company reported no debt financing or credit facility. Total liabilities were $12.4 million, including $5.1 million of operating lease liabilities. The company adopted ASC 842 in 2022 and recognized operating lease right-of-use assets and liabilities.
Material changes versus the prior comparable period
- Net loss increased 14% to $53.0 million, while total operating expenses increased 17% to $54.1 million.
- R&D expense increased 21% to $39.3 million, driven by increased staffing, clinical development and licensing activity.
- The company entered into an exclusive worldwide license agreement with IASO on October 7, 2022 for a fully human anti-CD19 binder used in CABA-201. The agreement included a $2.5 million upfront payment, potential milestone payments of up to $162 million in aggregate, and tiered mid-single-digit royalties.
- MuSK-CAART advanced into its Phase 1 clinical trial in November 2022 after receiving FDA Fast Track designation and Orphan Drug designation.
- DSG3-CAART monotherapy data through cohort A5 showed no dose-limiting toxicities up to a 7.5 billion-cell dose, but no clear overall trend in antibody levels or disease activity reduction.
- The company prioritized a DSG3-CAART combination sub-study using IVIG and cyclophosphamide pretreatment.
- In December 2022, the company raised $32.6 million in net proceeds through the sale of common stock and pre-funded warrants. It issued 126,815 common shares and pre-funded warrants for 6,213,776 shares; 271,739 warrants had been exercised by year-end.
- The company discontinued its FVIII product candidate to prioritize other programs.
- A securities class action filed in February 2022 concerning DSG3-CAART disclosures was voluntarily dismissed on October 17, 2022.
Guidance, outlook, commentary and risks
- Management stated that cash, cash equivalents and investments at December 31, 2022 were expected to fund operations into the first quarter of 2025, based on the current operating plan and assumptions. The filing also states that additional financing will be required to complete Phase 1 trials and advance the broader pipeline.
- Management expected to report one-month safety and persistence data from the DSG3-CAART combination sub-study in the first half of 2023 and six-month clinical data by the first half of 2024.
- Management expected six-month clinical data from the MuSK-CAART combination cohort by the first half of 2024.
- The filing does not provide revenue guidance because no product has been approved or commercialized and product revenue is not expected for several years, if at all.
- Clinical results remain early, based primarily on small, open-label Phase 1 studies. Preliminary or topline results may change as additional data become available.
- Key clinical risks include inadequate efficacy, limited CAART persistence or target engagement, cytokine release syndrome, neurotoxicity, autoimmune disease flares, adverse effects from preconditioning regimens, and patient enrollment delays.
- Manufacturing is complex and dependent on Penn, CHOP, WuXi and other third parties. Technology transfer, comparability, vector supply, capacity constraints and manufacturing failures could delay clinical development.
- The company relies substantially on in-licensed intellectual property from Penn, CHOP and IASO. Breach, termination, failure to meet diligence milestones, patent challenges or loss of license rights could materially impair the pipeline.
- Additional capital may be raised through equity, debt, collaborations or licensing arrangements. Future financing could dilute existing stockholders or impose restrictive terms.
- Other risks include regulatory uncertainty for novel autoimmune cell therapies, competition from CAR-T and other immunotherapies, changing reimbursement and drug-pricing policies, inflation, interest-rate volatility, cybersecurity incidents and disruptions affecting critical vendors.
- The company reported minimal exposure to the Silicon Valley Bank closure and no adverse impact on liquidity or operations as of the filing date.
Most important facts an investor should verify
- Whether CABA-201’s IND was cleared by the FDA in the first half of 2023 and the timing and quality of initial clinical data.
- Updated DSG3-CAART combination-sub-study safety, persistence, antibody and disease-activity results, including whether efficacy signals improve relative to monotherapy.
- MuSK-CAART enrollment, dosing, safety and early biologic-activity data from the MusCAARTes trial.
- Actual cash burn and remaining runway relative to the stated first-quarter 2025 estimate, including the timing and terms of future financing.
- Exercise of the remaining pre-funded warrants and the resulting fully diluted share count.
- Progress in transferring manufacturing from Penn and scaling vector and cell production through WuXi, Oxford Biomedica and other contract manufacturers.
- Continuing obligations and potential milestone, royalty and sublicense payments under the IASO, Penn, Oxford Biomedica and other agreements.
- Whether subsequent clinical, regulatory or litigation developments alter the risk profile described in the 10-K.